168263-86-3

Basic information

• Product Name: N⁴-benzoylcytosine-1-acetic acid
• Synonyms: N⁴-benzoylcytosine-1-acetic acid
• CAS NO: 168263-86-3
• Molecular Weight: 273.248
• Mol File: 168263-86-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N⁴-benzoylcytosine-1-acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: N⁴-benzoylcytosine-1-acetic acid(168263-86-3)
• EPA Substance Registry System: N⁴-benzoylcytosine-1-acetic acid(168263-86-3)

Safety Data

• Hazardous Substances Data: 168263-86-3(Hazardous Substances Data)

Upstream product

• 26661-13-2 4-N-benzoylcytosine 
• 98-88-4 benzoyl chloride 
• 186046-91-3 methyl (cytosine-1-yl)acetate 
• 168263-85-2 N₄-Benzoyl-1-tert-butyloxycarbonylmethylcytosine 

Downstream Products

• 184159-47-5 [([2-(4-Benzoylamino-2-oxo-2H-pyrimidin-1-yl)-acetyl]-{2-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-ethyl}-amino)-methyl]-phosphonic acid diphenyl ester 
• 857250-43-2 {[[2-(4-Benzoylamino-2-oxo-2H-pyrimidin-1-yl)-acetyl]-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-methyl}-phosphonic acid diphenyl ester 
• 1253933-48-0 C₃₈H₃₈N₄O₇ 
• 1280548-86-8 C₃₇H₃₆N₄O₇ 
• 1280548-93-7 C₄₆H₅₃N₆O₈P 
• 1362317-63-2 C₂₃H₃₃N₇O₄Si 
• 1362317-67-6 2-(N-((1-(2-(2-(N₄-(benzoyl)cytosin-1-yl)-N-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)acetamido)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-2-(uracil-1-yl)acetamido)ethyl (2-cyanoethyl)diisopropylphosphoramidite 
• 1362317-68-7 C₁₇H₁₉N₇O₄ 
• 1362317-64-3 N-(1-(2-((2-azidoethyl)(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)amino)-2-oxoethyl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide 
• 1362317-65-4 C₅₅H₆₄N₁₀O₁₀Si 
• 1362317-66-5 C₄₉H₅₀N₁₀O₁₀ 
• 1160163-44-9 C₄₄H₅₂N₆O₉ 
• 473268-79-0 2-({allyloxycarbonylmethyl-[(4-benzoylamino-2-oxo-2H-pyrimidin-1-yl)-acetyl]-amino}-methyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 172405-22-0 [[(4-benzoylamino-2-oxo-2H-pyrimidin-1-yl)-acetyl]-(2-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-ethyl)-amino]-acetic acid methyl ester 

Relevant articles and documents

Highly stable triple helix formation by homopyrimidine (l)-acyclic threoninol nucleic acids with single stranded DNA and RNA

Acyclic (l)-threoninol nucleic acid (aTNA) containing thymine, cytosine and adenine nucleobases were synthesized and shown to form surprisingly stable triplexes with complementary single stranded homopurine DNA or RNA targets. The triplex structures consist of two (l)-aTNA strands and one DNA or RNA, and these triplexes are significantly stronger than the corresponding DNA or RNA duplexes as shown in competition experiments. As a unique property the (l)-aTNAs exclusively form triplex structures with DNA and RNA and no duplex structures are observed by gel electrophoresis. The results were compared to the known enantiomer (d)-aTNA, which forms much weaker triplexes depending upon temperature and time. It was demonstrated that (l)-aTNA triplexes are able to stop primer extension on a DNA template, showing the potential of (l)-aTNA for antisense applications. This journal is

Efficient synthesis and cell-based silencing activity of siRNAS that contain triazole backbone linkages

An efficient synthesis of siRNAs modified at the backbone with a triazole functionality is reported. Through the use of 4,4×-dimethoxytrityl (DMT) phosphoramidite chemistry, triazole backbone dimmers were site-specifically incorporated throughout various siRNAs targeting both firefly luciferase and glyceraldehyde- 3-phosphate dehydrogenase (GAPDH) gene transcripts as representatives of an exogenous and endogenous gene, respectively. Following the successful silencing of the firefly luciferase reporter gene, triazole-modified siRNAs were also found to be capable of silencing GAPDH in a dose-dependent manner. Backbone modifications approaching the 3×-end on the sense strand were tolerated without compromising siRNA potency. This study highlights the compatibility of triazole-modified siRNAs within the RNAi pathway, and the modification's potential to impart favorable properties to siRNAs designed to target other endogenous genes.

Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics

The invention relates to nucleic acid-binding oligomers possessing N-branching of the general formula (I), STR1 and their monomers, where the individual radicals have the meaning given in the description, and to their use as medicaments or as aids in diag